Source:http://linkedlifedata.com/resource/pubmed/id/15090813
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2004-4-19
|
| pubmed:abstractText |
Potent antiretroviral therapy stimulates robust and durable immune reconstitution among profoundly immunosuppressed patients that is clinically important. Fifteen patients with cytomegalovirus retinitis (CMVR) were followed after discontinuing anti-cytomegalovirus therapy. No patients had progression or relapse for a median of 51 months. Survival from the diagnosis of CMVR was universal for up to 95 months, with an observation period averaging more than 6 years. The CD4 cell count continued to rise through the fourth year of follow-up.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0269-9370
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
20
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
567-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:15090813-AIDS-Related Opportunistic Infections,
pubmed-meshheading:15090813-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:15090813-CD4 Lymphocyte Count,
pubmed-meshheading:15090813-Cytomegalovirus Retinitis,
pubmed-meshheading:15090813-Follow-Up Studies,
pubmed-meshheading:15090813-Humans,
pubmed-meshheading:15090813-Immune Tolerance
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis.
|
| pubmed:affiliation |
The Critical Care Medicine Department, Clinical Center, National Institute of Allergy and Infectious Diseases, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
|
| pubmed:publicationType |
Journal Article
|